- Home
- XERS vs BHVN Comparison
XERS vs BHVN Comparison
Compare XERS & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | BHVN |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XERS | BHVN |
|---|---|---|
| Price | $7.28 | $12.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | $10.43 | ★ $30.36 |
| AVG Volume (30 Days) | 2.3M | ★ 3.2M |
| Earning Date | 03-02-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $266,137,000.00 | N/A |
| Revenue This Year | $44.77 | N/A |
| Revenue Next Year | $27.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.05 | N/A |
| 52 Week Low | $3.38 | $7.48 |
| 52 Week High | $10.08 | $44.28 |
Technical Indicators
Market Signals| Indicator | XERS | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 52.29 |
| Support Level | $7.36 | $10.35 |
| Resistance Level | $7.65 | $12.90 |
| Average True Range (ATR) | 0.30 | 1.12 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 18.37 | 48.95 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.